ArticleChemistry, an Asian journal2026
Enantioselective Gram-Scale Synthesis of Rasagiline via Chiral Phosphoric Acid-Catalyzed Reduction of Cyclic Imine.
Article in Chemistry, an Asian journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Rasagiline mesylate is a monoamine oxidase B inhibitor used clinically for treating Parkinson's disease. Conventional synthesis relies on optical resolution, which limits efficiency and scalability. To overcome these challenges, we developed an enantioselective synthesis route using asymmetric transfer hydrogenation (ATH) of a cyclic propargyl imine intermediate. Although cyclic imines are difficult to reduce due to their rigid structures, this challenge was overcome using a chiral phosphoric acid catalyst with a Hantzsch ester, affording chiral amines in high yield and enantioselectivity. The method was successfully scaled to the gram level, affording rasagiline mesylate with >96% enantiomeric excess. Furthermore, this approach showed broad substrate compatibility, underscoring its general utility in the asymmetric reduction of cyclic imine derivatives. Our strategy offers a practical and scalable alternative to existing methods for the synthesis of rasagiline and structurally related optically active amines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.